文献速递中医内科中药与中成药合理使用

派能达胶囊部分替代雄激素治疗慢性再生障碍性贫血的多中心临床研究

Treatment of Chronic Aplastic Anemia with Chinese Patent Medicine Pai-Neng-Da Capsule () for Replacing Androgen Partially: A Clinical Multi-Center Study.
PubMed 文献 · Chin J Integr Med · 2021-04-10

本多中心随机对照研究将79例慢性再生障碍性贫血患者分为派能达胶囊联合环孢素及低剂量安雄组(PCA组43例)与环孢素及常规剂量安雄组(CA组36例),治疗24周。结果显示两组有效率分别为88.1%与77.8%,外周血白细胞、血小板及血红蛋白无显著差异,但PCA组女性男性化评分显著低于CA组(P<0.05),提示派能达胶囊可部分替代雄激素并减轻男性化副作用。

要点

  • 派能达胶囊联合环孢素及低剂量安雄治疗慢性再障有效率达88.1%,与常规雄激素方案相当。
  • 派能达胶囊可部分替代安雄,显著降低女性患者男性化评分(P<0.05)。
  • 派能达胶囊不良反应轻微,仅见1例轻度腹胀,未见肝肾功能异常。

核心结论

  • 派能达胶囊治疗慢性再生障碍性贫血有一定疗效,无明显副作用,可部分替代安雄并降低男性化程度。

研究设计与样本

  • 多中心随机对照临床研究,79例慢性再生障碍性贫血患者按随机数字表分为PCA组43例和CA组36例,治疗随访24周(6个疗程)。
  • PCA组口服派能达胶囊320 mg/d加环孢素5 mg/(kg·d)加安雄80 mg/d;CA组口服环孢素5 mg/(kg·d)加安雄160 mg/d。

主要发现

  • 基于血液病疗效评价标准,PCA组有效率为88.1%(37/42),CA组为77.8%(28/36)。
  • 治疗6个月后两组外周血白细胞计数、血小板计数及血红蛋白浓度无显著差异。
  • PCA组女性患者男性化评分显著低于CA组(P<0.05)。
  • PCA组仅1例出现轻度腹胀;CA组2例出现肝功能异常,1例出现肾功能异常。

临床怎么用

  • 对于慢性再生障碍性贫血患者,可考虑派能达胶囊联合环孢素及低剂量安雄方案,以部分替代雄激素并减少男性化副作用。
  • 治疗期间需监测血常规、肝肾功能及女性男性化表现,安全性良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of Pai-Neng-Da Capsule (, panaxadiol saponins component, PNDC) in combination with the cyclosporine and androgen for patients with chronic aplastic anemia (CAA). METHODS: A total of 79 CAA patients was randomly divided into 2 groups by a random number table, including PCA group [43 cases, orally PNDC 320 mg/d plus cyclosporine 5 mg/(kg·d) plus andriol 80 mg/d] and CA group [36 cases, orally cyclosporine 5 mg/(kg·d) plus andriol 160 mg/d]. All patients were treated and followed-up for 6 treatment courses over 24 weeks. The complete blood counts, score of Chinese medical (CM) symptoms were assessed and urine routine, electrocardiogram, hepatic and renal function were observed for safety evaluation. Female masculinization rating scale was established according to the actual clinical manifestations to evaluate the accurate degree of masculinization in female CAA patients treated by andriol. RESULTS: The effective rates were 88.1% (37/42) in the PCA group and 77.8% (28/36) in the CA group based on the standard for the therapeutic efficacy evaluation of hematopathy. There was no significant difference in the white blood cell (WBC) counts, platelet counts and hemoglobin concentration of peripheral blood between two groups after 6 months treatment. The masculinization score of female patient in the PCA group was significantly lower than the CA group (P<0.05). The mild abdominal distention was observed in 1 cases in the PCA group. In CA group, the abnormalities in the hepatic function developed in 2 cases and the renal disfunction was found in 1 case. CONCLUSION: The PNDC possesses certain curative effects in the treatment of CAA without obvious side-effects and can partially replace andriol thereby to reduce the degree of masculinization [Registried at Chinese Clinical Trial Registry (ChicTR1900028153)].

来源:Chin J Integr Med,查看原文。版权归原作者所有。

引用

  1. Jiang ZY, Yu FQ, Gao RL, et al. Treatment of Chronic Aplastic Anemia with Chinese Patent Medicine Pai-Neng-Da Capsule () for Replacing Androgen Partially: A Clinical Multi-Center Study. Chin J Integr Med. 2021. PMID: 33837482. doi:10.1007/s11655-021-3283-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。